M. J. Pongers-Willemse
Erasmus University Rotterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. J. Pongers-Willemse.
Leukemia | 1998
M. J. Pongers-Willemse; O. J. H. M. Verhagen; G. J. M. Tibbe; A. J. M. Wijkhuijs; V de Haas; E. Roovers; C. E. Van Der Schoot; J J M van Dongen
Analysis of minimal residual disease (MRD) can predict outcome in acute lymphoblastic leukemia (ALL). A large prospective study in childhood ALL has shown that MRD analysis using immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements as PCR targets can identify good and poor prognosis groups of substantial size that might profit from treatment adaptation. This MRD-based risk group assignment was based on the kinetics of tumor reduction. Consequently, the level of MRD has to be defined precisely in follow-up samples. However, current PCR methods do not allow easy and accurate quantification. We have tested ‘real-time’ quantitative PCR (RQ-PCR) using the TaqMan technology and compared its sensitivity with two conventional MRD-PCR methods, ie dot-blot and liquid hybridization of PCR amplified Ig/TCR gene rearrangements using clone-specific radioactive probes. In RQ-PCR the generated specific PCR product is measured at each cycle (‘real-time’) by cleavage of a fluorogenic intrinsic TaqMan probe. The junctional regions of rearranged Ig/TCR genes define the specificity and sensitivity of PCR-based MRD detection in ALL and are generally used to design a patient-specific probe. In the TaqMan technology we have chosen for the same approach with the design of patient-specific TaqMan probes at the position of the junctional regions. We developed primers/probe combinations for RQ-PCR analysis of a total of three IGH, two TCRD, two TCRG and three IGK gene rearrangements in four randomly chosen precursor-B-ALL. In one patient, 12 bone marrow follow-up samples were analyzed for the presence of MRD using an IGK PCR target. The sensitivity of the RQ-PCR technique appeared to be comparable to the dot-blot method, but less sensitive than liquid hybridization. Although it still is a relatively expensive method, RQ-PCR allows sensitive, reproducible and quantitative MRD detection with a high throughput of samples providing possibilities for semi-automation. We consider this novel technique as an important step forward towards routinely performed diagnostic MRD studies.
Leukemia | 1997
Auke Beishuizen; Mac de Bruijn; M. J. Pongers-Willemse; M.-A. J. Verhoeven; E. R. Van Wering; K. Hählen; T. M. Breit; S. de Bruin-Versteeg; Herbert Hooijkaas; Jjm van Dongen
Virtually all immunoglobulin kappa (IGK) gene deletions are mediated via rearrangements of the so-called kappa deleting element (Kde). Kde rearrangements occur either to Vκ gene segments (Vκ–Kde rearrangements) or to the heptamer recombination signal sequence in the Jκ–Cκ intron. Kde rearrangements were analyzed by the polymerase chain reaction (PCR) and heteroduplex analysis in 130 B-lineage leukemias: 63 precursor-B-acute lymphoblastic leukemias (ALL) and 67 chronic B cell leukemias. To obtain detailed information about Kde rearrangements, we sequenced 109 of the 189 detected junctional regions. Vκ gene family usage in the Vκ–Kde rearrangements in our series of B-lineage leukemias was comparable to Vκ gene family usage in functional Vκ–Jκ rearrangements in normal and malignant mature B cells, except for a higher frequency of Vκ II family usage in precursor-B-ALL. Junctional region sequencing of the Kde rearrangements in precursor-B-ALL revealed a mean insertion of 4.7 nucleotides and a mean deletion of 9.5 nucleotides, resulting in an extensive junctional diversity, whereas in chronic B cell leukemias the insertion (1.9) and deletion (6.0) were significantly lower. The relatively extensive junctional diversity of the Kde rearrangements in precursor-B-ALL allowed us to design leukemia/patient-specific oligonucleotide probes, which were proven to be useful for detection of minimal residual disease (MRD) with sensitivities of 10−4 to 10−5. Kde rearrangements occur in approximately 50% of precursor-B-ALL cases and are likely to remain stable during the disease course, because Kde rearrangements are assumed to be ‘end-stage’ rearrangements, which cannot easily be replaced by continuing rearrangement processes. These findings indicate that junctional regions of Kde rearrangements in precursor-B-ALL represent new valuable patient-specific PCR targets for detection of MRD.
Leukemia | 1999
O. J. H. M. Verhagen; A. J. M. Wijkhuijs; A J van der Sluijs-Gelling; Tomasz Szczepański; B. E. M. van der Linden-Schrever; M. J. Pongers-Willemse; E. R. Van Wering; J J M van Dongen; C. E. Van Der Schoot
Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques
Current Topics in Microbiology and Immunology | 1999
Tomasz Szczepański; M. J. Pongers-Willemse; A W Langerak; J J M van Dongen
Immunoglobulin (Ig) and T-cell receptor (TCR) genes are rearranged in virtually all acute lymphoblastic leukemia (ALL) cases. However, the recombination patterns display several unusual features as compared to normal lymphoid counterparts. Cross-lineage gene rearrangements occur in more than 90% of precursor-B-ALL and in approximately 20% of T-ALL, whereas they are rare in normal lymphocytes. Approximately 25-30% of the Ig and TCR gene rearrangements at diagnosis are oligoclonal, and can undergo continuing or secondary recombination events during the disease course. Based on our extensive molecular studies we hypothesize that the unusual Ig and TCR gene rearrangements in ALL occur as an early postoncogenic event resulting from the continuing V(D)J recombinase activity on accessible gene loci. This hypothesis is on the one hand supported by the virtual absence of cross-lineage gene rearrangements in normal lymphocytes and mature lymphoid malignancies and on the other hand by the presence of oligoclonality and secondary Ig and TCR gene rearrangements in ALL.
Leukemia | 1999
T Szczepanski; A. Beishuizen; M. J. Pongers-Willemse; K. Hählen; E. R. Van Wering; A. J. M. Wijkhuijs; G. J. M. Tibbe; M. A. C. De Bruijn; J J M van Dongen
Blood | 1999
Tomasz Szczepański; M. J. Pongers-Willemse; Anton W. Langerak; Wietske A. Harts; Annemarie J.M. Wijkhuijs; Elisabeth R. van Wering; Jacques J.M. van Dongen
Cancer | 1998
Tomasz Szczepa ski; M. J. Pongers-Willemse; Karel Hhlen
The Lancet | 1999
T. Matsumura; M. Kami; T. Saito; H. Sakamaki; H. Hirai; J J M van Dongen; M. J. Pongers-Willemse; Andrea Biondi; E R Panzer-Grümayer; Claus R. Bartram
Cancer | 1998
T Szczepanski; M. J. Pongers-Willemse; K. Hählen; J. J. M. Van Dongen
Archive | 1988
J.J.M. (Jacques) van Dongen; W. van Ewijk; A W Langerak; M. J. Pongers-Willemse